An observational study in Carrier State and Respiratory Infections, sponsored by Philip Polgreen. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Philip Polgreen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 210 studies in Respiratory Tract Infections with a site in United States — 20 open to participants now, 28 under way, 5 of them phase 3. Respiratory Tract Infections · United States.
Among the 210 studies in Respiratory Tract Infections with a site in United States, this one is the 35th largest by planned enrollment of the 48 observational ones that give a count, is one of 6 that started in 2021, is one of 48 observational ones, reaches primary completion later than 6 of the 26 other live ones, and was the 168th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
Browse Respiratory Tract Infections studies →20 of the 210 studies in Respiratory Tract Infections with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 7–17 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
University Hospital, Grenoble · Sites in United States, France, Germany and 2 more countries
Ages 60+
Timothy Shope · Sites in United States
Ages 6 mo–24 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
210 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 42 · Phase 3 22 · Phase 4 14
First in 1997; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is below the median of 350 across 184 observational studies indexed under Respiratory Tract Infections.
Median enrollment 137 across the 160 interventional studies, 558 across the 48 observational. Of the 172 that completed or were terminated, 67 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
85 of 210 have an industry lead sponsor. The 10 most frequent:
Philip Polgreen is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Philip Polgreen has 1 study filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
14 of the studies in Respiratory Tract Infections with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05474430Philip PolgreenEstimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 210 studies in Respiratory Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays.
An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19.
The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.
CF Carriers and Controls who are not CF carriers.
CF Carrier Inclusion Criteria:
Control Group Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants have been identified as Cystic Fibrosis Carriers via previous genetic testing.
Participants have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.
Comparison of Chloride Transport Values
Comparison of chloride transport values in cystic fibrosis carrier group vs control group via t-test.
Time frame: At baseline
Comparison of Bicarbonate Transport Values
Comparison of bicarbonate transport values in cystic fibrosis carrier group vs control group via t-test.
Time frame: At baseline
Comparison of Airway Surface Liquid pH Values
Comparison of airway surface liquid pH values in cystic fibrosis carrier group vs control group via t-test.
Time frame: At baseline
Comparison of Mucous Viscosity Values
Comparison of mucous viscosity values in cystic fibrosis carrier group vs control group via t-test.
Time frame: At baseline
Comparison of Bacterial Killing Values
Comparison of bacterial killing values in cystic fibrosis carrier group vs control group via t-test.
Time frame: At baseline
Comparison of Fibroblast Growth Factor-19 Values
Comparison of fibroblast growth factor-19 values in cystic fibrosis carrier group vs control group via t-test.
Time frame: At baseline
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →